Valeant Abandoning its Growth by Acquisition Strategy -Reuters
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is putting aside its acquisition strategy, according to sources, as reported by Reuters. Valeant instead will focus on paying down dent and buying back shares.
Last month, Valeant lost out to Actavis plc (NYSE: ACT) in its bid to acquire Allergan Inc. (NYSE AGN).
Valeant closed Monday at $143.94, a loss of $0.95.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.